Moderna, Inc.,  a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today provided an update on the impact of the rapidly evolving COVID-19 pandemic on its business operations and clinical program development. Moderna’s paramount obligation is to ensure the safety of all participants in its clinical programs and the integrity of the studies in which they parti

Saniona, a clinical-stage biopharmaceutical company focused on rare diseases of the central nervous system, announced a new research collaboration with Boehringer Ingelheim in schizophrenia. Saniona can receive up to EUR 76.5 million in milestone payments as well as royalties on global net sales for the products developed in the collaboration. The goal is to identify new treatment options for schizophrenia by exploring a new ion channel target in the CNS with Saniona's drug disc

Debiopharm, a Swiss-based biopharmaceutical company, announced today having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program, now called Debio 0228, which targets the CAIX (Carbonic Anhydrase 9) enzyme to fight the progression of cancer. This agreement extends the radio-oncology portfolio of Debiopharm which currently includes another clinical stage radiother

Hoth Therapeutics, Inc., a biopharmaceutical company, today announced it has reached an agreement with Voltron Therapeutics, Inc. (Voltron) to form a joint venture entity, to be named HaloVax, to commence preclinical studies for the development of vaccine prospects to prevent the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).

BONE THERAPEUTICS , the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces it has received regulatory approvals for its Clinical Trial Applications for the next studies of both of its lead candidates. These two studies are the pivotal JTA-004 Phase III clinical study targeting osteoarthritic knee pain and the Phase IIb study of its allogeneic cell therapy product, ALLOB, in patients with difficult tibial fractures. The JTA-004 tria

As part of the U.S. Food and Drug Administration's ongoing commitment to address the coronavirus (COVID-19) pandemic, the agency has issued two guidance documents to communicate its policy for the temporary manufacture of certain alcohol-based hand sanitizer products. These guidance documents will be in effect for the duration of the public health emergency declared by the Secretary of Health and Human Services (HHS) on January 31, 2020. "We are aware of significant supply

Following the successful early-stage validation of Cyclica’s Ligand Express® platform from an initial collaboration, NeuroTheryX Canada Ltd. (NeuroTheryX) and Cyclica, Inc. (Cyclica) form a new joint venture, NineteenGale Therapeutics (NineteenGale) to identify and develop novel cannabinoid-inspired drugs for bipolar disorder, anxiety, and pain management. Under the initial stealth project, NeuroTheryX combined their phenotype-based drug discovery platform with Cyclica’s first

Portola Pharmaceuticals, Inc announced proactive steps the Company is taking in support of public health efforts to prevent furtherspread of coronavirus (or COVID-19) around the globe. As this global pandemic evolves rapidly, Portola's first priority is the health and safety of employees, patients and healthcare providers. To align with growing rigorous regulations at the global, federal and local level around the COVID-19 global pandemic, we have taken proactive steps to help h

Luina Bio is delighted to announce they have entered into a MoU with Griffith University targeting the development of a Coronavirus vaccine. With COVID-19 now declared as a pandemic and world financial markets stumbling, the collaboration between Luina Bio and Griffith University combining Luina Bio’s leadership position in the Australian biopharmaceutical industry with the strength of Griffith University’s rapid response technology has the potential to make a significan

Moleculin Biotech, Inc.,, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that it has entered into an agreement with the University of Texas Medical Branch at Galveston (UTMB) to conduct research on Moleculin's patented portfolio of molecular inhibitors, including drug candidate, WP1122, for antiviral properties against a range of viruses, including Coronavirus.  UTMB's Center for Biodefense and Emergi